BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 36692150)

  • 21. Maternal and Fetal Exposure to (-)-Δ
    Chen X; Unadkat JD; Mao Q
    Drug Metab Dispos; 2023 Mar; 51(3):269-275. PubMed ID: 36446608
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of the breast cancer resistance protein (ABCG2) in the distribution of sorafenib to the brain.
    Agarwal S; Sane R; Ohlfest JR; Elmquist WF
    J Pharmacol Exp Ther; 2011 Jan; 336(1):223-33. PubMed ID: 20952483
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Estimation of Fetal-to-Maternal Unbound Steady-State Plasma Concentration Ratio of P-Glycoprotein and/or Breast Cancer Resistance Protein Substrate Drugs Using a Maternal-Fetal Physiologically Based Pharmacokinetic Model.
    Peng J; Ladumor MK; Unadkat JD
    Drug Metab Dispos; 2022 May; 50(5):613-623. PubMed ID: 35149540
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quantitative evaluation of the impact of active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier on the predictability of the unbound concentrations of drugs in the brain using cerebrospinal fluid concentration as a surrogate.
    Kodaira H; Kusuhara H; Fujita T; Ushiki J; Fuse E; Sugiyama Y
    J Pharmacol Exp Ther; 2011 Dec; 339(3):935-44. PubMed ID: 21934030
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug transport across the blood-brain barrier and the impact of breast cancer resistance protein (ABCG2).
    Nicolazzo JA; Katneni K
    Curr Top Med Chem; 2009; 9(2):130-47. PubMed ID: 19200001
    [TBL] [Abstract][Full Text] [Related]  

  • 26. P-glycoprotein mediated efflux limits the transport of the novel anti-Parkinson's disease candidate drug FLZ across the physiological and PD pathological in vitro BBB models.
    Liu Q; Hou J; Chen X; Liu G; Zhang D; Sun H; Zhang J
    PLoS One; 2014; 9(7):e102442. PubMed ID: 25036090
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Species difference in brain penetration of P-gp and BCRP substrates among monkey, dog and mouse.
    Kido Y; Nanchi I; Fusamae Y; Matsuzaki T; Akazawa T; Sawada H; Iwasaki M; Nishida K; Tsuchiya E; Okuda T
    Drug Metab Pharmacokinet; 2022 Feb; 42():100426. PubMed ID: 34974334
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tetrahydrocannabinol and Its Major Metabolites Are Not (or Are Poor) Substrates or Inhibitors of Human P-Glycoprotein [ATP-Binding Cassette (ABC) B1] and Breast Cancer Resistance Protein (ABCG2).
    Chen X; Unadkat JD; Mao Q
    Drug Metab Dispos; 2021 Oct; 49(10):910-918. PubMed ID: 34326138
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PET-CT imaging with [(18)F]-gefitinib to measure Abcb1a/1b (P-gp) and Abcg2 (Bcrp1) mediated drug-drug interactions at the murine blood-brain barrier.
    Vlaming ML; Läppchen T; Jansen HT; Kivits S; van Driel A; van de Steeg E; van der Hoorn JW; Sio CF; Steinbach OC; DeGroot J
    Nucl Med Biol; 2015 Nov; 42(11):833-41. PubMed ID: 26264927
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Abundance of P-Glycoprotein and Other Drug Transporters at the Human Blood-Brain Barrier in Alzheimer's Disease: A Quantitative Targeted Proteomic Study.
    Storelli F; Billington S; Kumar AR; Unadkat JD
    Clin Pharmacol Ther; 2021 Mar; 109(3):667-675. PubMed ID: 32885413
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A combo-strategy to improve brain delivery of antiepileptic drugs: Focus on BCRP and intranasal administration.
    Gonçalves J; Silva S; Gouveia F; Bicker J; Falcão A; Alves G; Fortuna A
    Int J Pharm; 2021 Jan; 593():120161. PubMed ID: 33307160
    [TBL] [Abstract][Full Text] [Related]  

  • 32. P-glycoprotein and breast cancer resistance protein affect disposition of tandutinib, a tyrosine kinase inhibitor.
    Yang JJ; Milton MN; Yu S; Liao M; Liu N; Wu JT; Gan L; Balani SK; Lee FW; Prakash S; Xia CQ
    Drug Metab Lett; 2010 Dec; 4(4):201-12. PubMed ID: 20670210
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone.
    Kodaira H; Kusuhara H; Ushiki J; Fuse E; Sugiyama Y
    J Pharmacol Exp Ther; 2010 Jun; 333(3):788-96. PubMed ID: 20304939
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biochemical interaction of anti-HCV telaprevir with the ABC transporters P-glycoprotein and breast cancer resistance protein.
    Fujita Y; Noguchi K; Suzuki T; Katayama K; Sugimoto Y
    BMC Res Notes; 2013 Nov; 6():445. PubMed ID: 24196382
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An electrically tight in vitro blood-brain barrier model displays net brain-to-blood efflux of substrates for the ABC transporters, P-gp, Bcrp and Mrp-1.
    Helms HC; Hersom M; Kuhlmann LB; Badolo L; Nielsen CU; Brodin B
    AAPS J; 2014 Sep; 16(5):1046-55. PubMed ID: 24934296
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterisation of the brain multidrug resistance protein (BMDP/ABCG2/BCRP) expressed at the blood-brain barrier.
    Eisenblätter T; Hüwel S; Galla HJ
    Brain Res; 2003 May; 971(2):221-31. PubMed ID: 12706238
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Brain distribution of cediranib is limited by active efflux at the blood-brain barrier.
    Wang T; Agarwal S; Elmquist WF
    J Pharmacol Exp Ther; 2012 May; 341(2):386-95. PubMed ID: 22323823
    [TBL] [Abstract][Full Text] [Related]  

  • 38. (18)F-FCWAY, a serotonin 1A receptor radioligand, is a substrate for efflux transport at the human blood-brain barrier.
    Liow JS; Zoghbi SS; Hu S; Hall MD; Hines CS; Shetty HU; Araneta MD; Page EM; Pike VW; Kreisl WC; Herscovitch P; Gottesman MM; Theodore WH; Innis RB
    Neuroimage; 2016 Sep; 138():134-140. PubMed ID: 27211474
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression, up-regulation, and transport activity of the multidrug-resistance protein Abcg2 at the mouse blood-brain barrier.
    Cisternino S; Mercier C; Bourasset F; Roux F; Scherrmann JM
    Cancer Res; 2004 May; 64(9):3296-301. PubMed ID: 15126373
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Practical Perspective on the Evaluation of Small Molecule CNS Penetration in Drug Discovery.
    Huang L; Wells MC; Zhao Z
    Drug Metab Lett; 2019; 13(2):78-94. PubMed ID: 30854983
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.